Delving into the Latest Updates on IPS101A with Synapse

Overview

Basic Info

Drug Type

AAV based gene therapy

Synonyms

IPS101A

Target-

Action-

Mechanism-

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic Disease

Active Indication

Parkinson Disease

Inactive Indication-

Originator Organization

Innopeutics Co. Ltd.

Active Organization

Innopeutics Co. Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Dose-Escalation, Single-Center, Open-label Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Adeno-associated Virus(AAV) Gene Therapy Product IPS101A in Parkinson's Disease Patients With Hoehn-Yahr Stage 4-5, Diagnosed in More Than 10 Years and Uncontrolled by All Available Monotherapy or Combination Therapy

The purpose of this study is to evaluate the dose-related safety and tolerability of IPS101A, an adeno-associated virus (AAV) gene therapy, in patients with Parkinson's disease who exhibit severe functional impairment corresponding to Hoehn & Yahr stages 4-5 and whose symptoms are not adequately controlled despite all available monotherapy and combination therapy options. In addition, the study aims to assess the maximum tolerated dose (MTD) of IPS101A, as well as its preliminary efficacy and pharmacokinetic (PK) characteristics.

Start Date30 May 2026

Sponsor / Collaborator

Innopeutics Co. Ltd.

100 Clinical Results associated with IPS101A

Login to view more data

100 Translational Medicine associated with IPS101A

Login to view more data

100 Patents (Medical) associated with IPS101A

Login to view more data

100 Deals associated with IPS101A

Login to view more data